Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.64 is 49% above its 5-year average of -3.21, near the high end of its 5-year range (-6.03–-1.64).
11.83% above its 12-month average of -1.86.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.49.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.64
EARNINGS PER SHARE (EPS) AVG TTM
-1.86
EARNINGS PER SHARE (EPS) AVG 3Y
-2.94
EARNINGS PER SHARE (EPS) AVG 5Y
-3.21
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.83%
CURRENT VS 3Y AVG
+44.22%
CURRENT VS 5Y AVG
+48.86%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Enliven Therapeutics, Inc.
Market Cap
$3.25B
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.86
3Y Avg
-2.94
5Y Avg
-3.21
Market Cap
$3.16B
Earnings Per Share (EPS)
-2.84
TTM Avg
-2.77
3Y Avg
-2.30
5Y Avg
-1.82
Market Cap
$3.15B
Earnings Per Share (EPS)
0.21
TTM Avg
-0.65
3Y Avg
-2.68
5Y Avg
-3.12
Market Cap
$3.09B
Earnings Per Share (EPS)
-1.41
TTM Avg
-2.98
3Y Avg
-2.05
5Y Avg
-1.75
Market Cap
$3.44B
Earnings Per Share (EPS)
2.22
TTM Avg
1.84
3Y Avg
0.49
5Y Avg
-0.14
Market Cap
$3.59B
Earnings Per Share (EPS)
-4.29
TTM Avg
-3.30
3Y Avg
-2.99
5Y Avg
-2.52
Market Cap
$2.88B
Earnings Per Share (EPS)
-3.33
TTM Avg
-3.42
3Y Avg
-3.51
5Y Avg
-3.03
Market Cap
$3.62B
Earnings Per Share (EPS)
-1.94
TTM Avg
-2.32
3Y Avg
-2.00
5Y Avg
-1.79
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.25B | -1.64 | -1.86 | -2.94 | -3.21 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -2.84 | -2.77 | -2.30 | -1.82 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | 0.21 | -0.65 | -2.68 | -3.12 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -1.41 | -2.98 | -2.05 | -1.75 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 2.22 | 1.84 | 0.49 | -0.14 |
| Celcuity Inc. (CELC)vs › | $3.59B | -4.29 | -3.30 | -2.99 | -2.52 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | -3.33 | -3.42 | -3.51 | -3.03 |
| CareDx, Inc (CDNA)vs › | $3.61B | 2.07 | 0.30 | -1.10 | -0.90 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.62B | -1.94 | -2.32 | -2.00 | -1.79 |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 3.86 | 3.33 | 1.17 | 0.32 |
Trailing EPS (TTM)
$-1.64
Forward EPS (Est.)
$-1.84
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.83 |
| 2024-12-31 | -1.89 |
| 2023-12-31 | -2.01 |
| 2022-12-31 | -6.03 |
| 2021-12-31 | -3.17 |
| 2020-12-31 | -4.31 |
| 2019-12-31 | -5.43 |
| 2018-12-31 | -2.62 |
| 2017-12-31 | 0.00 |
